Sarepta Therapeutics (NASDAQ:SRPT) Rating Reiterated by Royal Bank of Canada

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sector perform” rating reissued by equities researchers at Royal Bank of Canada in a note issued to investors on Tuesday, MarketBeat reports. They currently have a $142.00 price target on the biotechnology company’s stock, down from their prior price target of $157.00. Royal Bank of […]

Related Keywords

Canada ,Bilal Arif ,Securities Exchange Commission ,Royal Bank ,Principal Securities Inc ,Jpmorgan Chase Co ,Mather Group ,Partners Investment Advisory ,Sarepta Therapeutics Inc ,Riggs Asset Managment Co ,Montaga Associates Inc ,Citigroup ,Sarepta Therapeutics ,Get Free Report ,Dallan Murray ,Exchange Commission ,Asset Managment ,Cary Street Partners Investment Advisory ,Street Partners Investment Advisory ,Sarepta Therapeutics Daily ,